- Home
- QURE vs COLL Comparison
QURE vs COLL Comparison
Compare QURE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | COLL |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QURE | COLL |
|---|---|---|
| Price | $25.30 | $45.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $58.55 | $51.17 |
| AVG Volume (30 Days) | ★ 1.7M | 493.0K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $15,751,000.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.17 |
| Revenue Next Year | $142.93 | $3.65 |
| P/E Ratio | ★ N/A | $27.99 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $7.76 | $23.23 |
| 52 Week High | $71.50 | $50.79 |
Technical Indicators
Market Signals| Indicator | QURE | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 45.69 |
| Support Level | $21.64 | $44.43 |
| Resistance Level | $25.80 | $48.29 |
| Average True Range (ATR) | 1.74 | 2.05 |
| MACD | 0.47 | -0.22 |
| Stochastic Oscillator | 53.94 | 28.48 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.